Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM-001 in GvHD
NCT05276076Phase 2Not yet recruiting
- Sponsor
- ViGenCell Inc.
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Native Immune Cells
01
Overview
A Phase 2 trial of VM-001 in graft-versus-host disease (GVHD), sponsored by ViGenCell Inc.. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
VM-001
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05276076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276076.